1. Home
  2. AGEN vs SRG Comparison

AGEN vs SRG Comparison

Compare AGEN & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.47

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

SRG

Seritage Growth Properties

HOLD

Current Price

$2.61

Market Cap

142.5M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGEN
SRG
Founded
1994
2014
Country
United States
United States
Employees
N/A
5
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
142.5M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
AGEN
SRG
Price
$3.47
$2.61
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$14.50
N/A
AVG Volume (30 Days)
889.8K
239.7K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
N/A
EPS
1.02
N/A
Revenue
$42,877,086.00
N/A
Revenue This Year
$107.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.48
N/A
Revenue Growth
89.95
N/A
52 Week Low
$2.71
$2.43
52 Week High
$7.34
$4.56

Technical Indicators

Market Signals
Indicator
AGEN
SRG
Relative Strength Index (RSI) 42.93 46.71
Support Level $2.91 $2.43
Resistance Level $4.72 $2.75
Average True Range (ATR) 0.25 0.08
MACD -0.07 0.00
Stochastic Oscillator 24.30 47.37

Price Performance

Historical Comparison
AGEN
SRG

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

About SRG Seritage Growth Properties

Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.

Share on Social Networks: